DE69631786D1 - Über die lungen verabreichbares trockenpulver alpha 1-antitrypsin - Google Patents

Über die lungen verabreichbares trockenpulver alpha 1-antitrypsin

Info

Publication number
DE69631786D1
DE69631786D1 DE69631786T DE69631786T DE69631786D1 DE 69631786 D1 DE69631786 D1 DE 69631786D1 DE 69631786 T DE69631786 T DE 69631786T DE 69631786 T DE69631786 T DE 69631786T DE 69631786 D1 DE69631786 D1 DE 69631786D1
Authority
DE
Germany
Prior art keywords
alpha
dry powder
lung
antitrypsin
powder available
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69631786T
Other languages
English (en)
Other versions
DE69631786T3 (de
DE69631786T2 (de
Inventor
Jamal Mohamed El
S Patton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27026029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69631786(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/423,515 external-priority patent/US6582728B1/en
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of DE69631786D1 publication Critical patent/DE69631786D1/de
Application granted granted Critical
Publication of DE69631786T2 publication Critical patent/DE69631786T2/de
Publication of DE69631786T3 publication Critical patent/DE69631786T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0086—Inhalation chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/07—General characteristics of the apparatus having air pumping means
    • A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
    • A61M2205/073—Syringe, piston type
DE69631786T 1995-04-14 1996-04-11 Über die lungen verabreichbares trockenpulver alpha 1-antitrypsin Expired - Lifetime DE69631786T3 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US423515 1995-04-14
US08/423,515 US6582728B1 (en) 1992-07-08 1995-04-14 Spray drying of macromolecules to produce inhaleable dry powders
US08/617,512 US5780014A (en) 1995-04-14 1996-03-13 Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US617512 1996-03-13
PCT/US1996/005062 WO1996032152A1 (en) 1995-04-14 1996-04-11 Pulmonary administration of dry powder alpha 1-antitrypsin

Publications (3)

Publication Number Publication Date
DE69631786D1 true DE69631786D1 (de) 2004-04-08
DE69631786T2 DE69631786T2 (de) 2005-03-10
DE69631786T3 DE69631786T3 (de) 2008-07-24

Family

ID=27026029

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69631786T Expired - Lifetime DE69631786T3 (de) 1995-04-14 1996-04-11 Über die lungen verabreichbares trockenpulver alpha 1-antitrypsin

Country Status (12)

Country Link
US (2) US5780014A (de)
EP (1) EP0866726B2 (de)
JP (1) JPH10509738A (de)
KR (1) KR100430125B1 (de)
AT (1) ATE260688T1 (de)
AU (1) AU703491B2 (de)
BR (1) BR9609497A (de)
CA (1) CA2218208A1 (de)
DE (1) DE69631786T3 (de)
ES (1) ES2217309T5 (de)
MX (1) MX9707854A (de)
WO (1) WO1996032152A1 (de)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
DK0877602T3 (da) 1996-01-24 2002-05-06 Byk Gulden Lomberg Chem Fab Fremgangsmåde til fremstilling af pulverformede lungesurfactant-præparater
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US20010006939A1 (en) * 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
WO1999055310A1 (en) 1998-04-27 1999-11-04 Altus Biologics Inc. Stabilized protein crystals, formulations containing them and methods of making them
GB9808802D0 (en) * 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
US6391861B1 (en) 1998-05-14 2002-05-21 The Trustees Of Columbia University In The City Of New York Method for the prevention of tissue elastic fiber injury
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US20020006901A1 (en) * 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
ATE555773T1 (de) 1999-06-09 2012-05-15 Sievers Robert E Überkritische fluidgestützte verneblung und blasen trochnen
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
JP2003507410A (ja) * 1999-08-25 2003-02-25 アドバンスト インハレーション リサーチ，インコーポレイテッド 乾燥粉末製剤からの放出調節
US6679256B2 (en) * 1999-12-17 2004-01-20 Nektar Therapeutics Systems and methods for extracting powders from receptacles
CN1230197C (zh) * 1999-12-30 2005-12-07 英特芒尼公司 γ－IFN水溶液液滴气溶胶及其生产方法
WO2001051510A2 (en) 2000-01-10 2001-07-19 Maxygen Holdings Ltd G-csf conjugates
AU2001237050A1 (en) * 2000-02-17 2001-08-27 Genzyme Corporation Genetic modification of the lung as a portal for gene delivery
WO2001085136A2 (en) 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US6668827B2 (en) * 2000-05-16 2003-12-30 Nektar Therapeutics Systems devices and methods for opening receptacles having a powder to be fluidized
WO2001093846A2 (en) * 2000-05-23 2001-12-13 The Trustees Of Columbia University In The City Of New York Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans
GB2362884A (en) * 2000-05-30 2001-12-05 Isis Innovation Extended duration of airway gene therapy
DE10043509A1 (de) * 2000-09-01 2002-03-14 Asta Medica Ag Feste Peptidzubereitungen für die Inhalation und deren Herstellung
WO2002032406A2 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
EP2080771A3 (de) 2001-02-27 2010-01-06 Maxygen Aps Neue Interferon-betaartige Moleküle
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
USD466607S1 (en) 2001-08-27 2002-12-03 Kimberly-Clark Worldwide, Inc. Flexible connector
USD486909S1 (en) 2001-08-27 2004-02-17 Kimberly-Clark Worldwide, Inc. Bendable connecting device
USD473941S1 (en) 2001-08-27 2003-04-29 Kimberly-Clark Worldwide, Inc. Flexible connecting device
USD476731S1 (en) 2001-08-27 2003-07-01 Kimberly-Clark Worldwide, Inc. Bendable connector
AU2002346472A1 (en) * 2001-11-20 2003-06-10 Advanced Inhalation Research, Inc. Particulate compositions for improving solubility of poorly soluble agents
US7182961B2 (en) * 2001-11-20 2007-02-27 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
JP2005533013A (ja) * 2002-04-19 2005-11-04 イスム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティ オブ エルサレム 一酸化窒素供与基および反応性酸素種捕捉基を含有するβ作用薬化合物、ならびに呼吸障害の治療における該化合物の使用
CA2483271A1 (en) * 2002-04-25 2003-11-06 Momenta Pharmaceuticals, Inc. Methods and products for mucosal delivery
WO2003090695A2 (en) 2002-04-25 2003-11-06 Transkaryotic Therapies, Inc. TREATMENT OF α-GALACTOSIDASE A DEFICIENCY
US6889690B2 (en) * 2002-05-10 2005-05-10 Oriel Therapeutics, Inc. Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages
US7118010B2 (en) 2002-05-10 2006-10-10 Oriel Therapeutics, Inc. Apparatus, systems and related methods for dispensing and /or evaluating dry powders
US7677411B2 (en) 2002-05-10 2010-03-16 Oriel Therapeutics, Inc. Apparatus, systems and related methods for processing, dispensing and/or evaluatingl dry powders
US6985798B2 (en) 2002-05-10 2006-01-10 Oriel Therapeutics, Inc. Dry powder dose filling systems and related methods
EP1535349B1 (de) 2002-06-27 2014-06-25 Oriel Therapeutics, Inc. Geräte, systeme und relevante verfahren für die aufbereitung, ausgabe und/oder beurteilung von nichtpharmazeutischen trockenpulvern
AU2003278565A1 (en) * 2002-10-25 2004-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
US7777006B2 (en) 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
EP3178486B1 (de) 2003-01-31 2018-06-06 Mount Sinai School of Medicine of New York University Kombinationstherapie zur behandlung von proteinmangelstörungen
US20040170214A1 (en) * 2003-02-27 2004-09-02 Richard Rund Food safety thermometer
ATE433759T1 (de) 2003-04-18 2009-07-15 Biogen Idec Inc Polymerkonjugiertes glycosiliertes neublastin
EP1624866A2 (de) * 2003-05-16 2006-02-15 Arriva Pharmaceuticals, Inc. Behandlung von atemwegserkrankungen durch inhalation von syntetischen matrix metalloprotease inhibitoren
US8075919B2 (en) * 2003-07-18 2011-12-13 Baxter International Inc. Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
CA2534352A1 (en) 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
JP2007517771A (ja) * 2003-10-01 2007-07-05 モメンタ ファーマシューティカルズ インコーポレイテッド 活性物質を肺送達するための多糖
US7377277B2 (en) 2003-10-27 2008-05-27 Oriel Therapeutics, Inc. Blister packages with frames and associated methods of fabricating dry powder drug containment systems
CA2545458A1 (en) * 2003-11-10 2005-05-26 Arriva-Prometic Inc. Dry recombinant human alpha 1-antitrypsin formulation
WO2005049801A2 (en) * 2003-11-14 2005-06-02 Arriva Pharmaceuticals, Inc. Dry protein formulation
PL1684719T3 (pl) * 2003-11-14 2012-11-30 Baxalta Inc Kompozycje alfa 1-antytrypsyny i sposoby leczenia z zastosowaniem takich kompozycji
AU2005221151A1 (en) 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
AU2005229434B2 (en) 2004-03-30 2010-09-30 Nsgene A/S Therapeutic use of a growth factor, NsG33
CA2910494C (en) 2004-07-19 2018-10-23 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
US20090136552A1 (en) * 2004-07-30 2009-05-28 Mette Gronborg Growth factors nsg28, nsg30, and nsg32
US8722862B2 (en) 2004-08-19 2014-05-13 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
BRPI0514534A (pt) * 2004-08-19 2008-06-17 Biogen Idec Inc variantes de neublastina
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
UA95446C2 (ru) 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Мутаци в генах oas1
WO2006125141A2 (en) 2005-05-17 2006-11-23 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin derivatives
US20100119525A1 (en) * 2005-08-01 2010-05-13 Mount Sinai Schoool Of Medicine Of New York University Method for extending longevity using npc1l1 antagonists
WO2007019554A2 (en) * 2005-08-08 2007-02-15 Momenta Pharmaceuticals, Inc. Polysaccharides for delivery of active agents
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US20080103746A1 (en) 2005-11-30 2008-05-01 Searete Llc, A Limited Liability Corporation Systems and methods for pathogen detection and response
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
EP1991532B1 (de) 2006-02-24 2017-01-11 Rigel Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung des jak-pfades
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
NZ580947A (en) 2007-05-01 2012-05-25 Biogen Idec Inc Compositions and methods for increasing vascularization
US20110135648A1 (en) * 2007-08-08 2011-06-09 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
NZ582170A (en) 2007-08-17 2012-02-24 Csl Behring Gmbh Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i
EP2207890A4 (de) 2007-10-05 2010-12-15 Barofold Inc Hochdruckbehandlung aggregierter interferone
PT2389372E (pt) 2009-01-23 2016-01-07 Rigel Pharmaceuticals Inc Composições e métodos para a inibição da via jak
NZ595629A (en) 2009-04-09 2013-04-26 Amicus Therapeutics Inc Methods for preventing and/or treating lysosomal storage disorders
WO2010142017A1 (en) 2009-06-09 2010-12-16 Defyrus, Inc . Administration of interferon for prophylaxis against or treatment of pathogenic infection
JP5656996B2 (ja) 2009-07-13 2015-01-21 ザ ユニバーシティ オブ ノース キャロライナ アット チャペル ヒル 工学的に作製されたエアロゾル粒子、およびそれに関連した方法
RU2581058C2 (ru) 2009-10-19 2016-04-10 Амикус Терапьютикс, Инк. Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы
DK2490533T3 (en) 2009-10-19 2015-12-07 Amicus Therapeutics Inc NOVEL COMPOSITIONS FOR PREVENTION AND / OR TREATMENT OF Lysosomal Storage DISEASES
JP2013518097A (ja) 2010-01-26 2013-05-20 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー 肺高血圧を予防および治療するための組成物および方法
CN103339149B (zh) 2010-06-14 2016-02-03 H.隆德贝克有限公司 SorLA和GDNF-家族配体受体之间的相互作用的调节
CA2754237A1 (en) 2011-05-27 2012-11-27 The Regents Of The University Of California Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
WO2013098672A2 (en) 2011-12-30 2013-07-04 Grifols, S.A. Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
WO2013114371A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Dry powder formulations of dnase i
AU2013235729B2 (en) 2012-03-23 2017-06-01 Baylor University Compositions and methods for inhibition of cathepsins
CA2868459A1 (en) 2012-03-27 2013-10-03 Amicus Therapeutics, Inc. Polymorphs of (3r,4r,5s)-5-(difluoromethyl)piperidine-3,4-diol fumarate and uses thereof
JP6561378B2 (ja) 2012-06-08 2019-08-21 トランスレイト バイオ， インコーポレイテッド 非肺標的細胞へのｍＲＮＡの経肺送達
CA2939380A1 (en) 2014-02-12 2015-08-20 Amicus Therapeutics, Inc. Sugar derivatives comprising sulfur-containing moieties and methods of making same and methods of using the same for the treatment of mps iiic
US9675627B2 (en) 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
WO2016057693A1 (en) 2014-10-10 2016-04-14 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhalation delivery of conjugated oligonucleotide
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
SG11201707663SA (en) 2015-04-17 2017-11-29 Curevac Ag Lyophilization of rna
SG11201708540VA (en) 2015-05-20 2017-12-28 Curevac Ag Dry powder composition comprising long-chain rna
EP3928800A3 (de) 2015-05-20 2022-03-23 CureVac AG Trockenpulverzusammensetzung mit langkettiger rna
US10179128B2 (en) 2015-08-31 2019-01-15 Amicus Therapeutics, Inc. Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
IL267520B2 (en) * 2016-12-22 2023-09-01 Kamada Ltd Dry powder composition of alpha-1 antitrypsin
KR20190108104A (ko) 2016-12-31 2019-09-23 바이오엑셀 테라퓨틱스 인코포레이티드 불안의 치료를 위한 설하 덱스메데토미딘의 용도
AU2018258348B2 (en) 2017-04-25 2022-07-07 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders
CN114983981A (zh) 2018-06-27 2022-09-02 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
WO2020092845A1 (en) 2018-11-01 2020-05-07 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
US11160791B2 (en) 2018-11-01 2021-11-02 Medefil, Inc. Dexmedetomidine injection premix formulation in ready to use (RTU) bags
WO2020214946A1 (en) 2019-04-18 2020-10-22 Translate Bio, Inc. Cystine cationic lipids
US20220233444A1 (en) 2019-04-22 2022-07-28 Translate Bio, Inc. Thioester cationic lipids
US20220257724A1 (en) 2019-05-03 2022-08-18 Translate Bio, Inc. Di-thioester cationic lipids
WO2020243612A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
WO2020243540A1 (en) 2019-05-31 2020-12-03 Translate Bio, Inc. Macrocyclic lipids
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
BR112022001418A2 (pt) 2019-08-08 2022-06-07 Rigel Pharmaceuticals Inc Compostos e método para tratar a síndrome de liberação de citocinas
WO2021030526A1 (en) 2019-08-14 2021-02-18 Rigel Pharmaceuticals, Inc. Method of blocking or ameliorating cytokine release syndrome
JP2023520047A (ja) 2020-04-01 2023-05-15 トランスレイト バイオ， インコーポレイテッド フェノール酸脂質系カチオン性脂質
AU2021349262A1 (en) 2020-09-23 2023-06-08 Translate Bio, Inc. Piperazine-based cationic lipids
JP2023542945A (ja) 2020-09-23 2023-10-12 トランスレイト バイオ， インコーポレイテッド Ｔｅｓベースのカチオン性脂質
TW202309002A (zh) 2021-04-15 2023-03-01 美商轉譯生技公司 基於「古德」緩衝液的陽離子脂質
WO2023178167A1 (en) 2022-03-16 2023-09-21 Translate Bio, Inc. Asymmetric piperazine-based cationic lipids
WO2023183377A1 (en) 2022-03-23 2023-09-28 Rigel Pharmaceuticals, Inc. Pyrimid-2-yl-pyrazole compounds as irak inhibitors
WO2023198857A1 (en) 2022-04-13 2023-10-19 Sanofi "good" buffer-based cationic lipids

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2598525A (en) * 1950-04-08 1952-05-27 E & J Mfg Co Automatic positive pressure breathing machine
US3362405A (en) * 1964-04-06 1968-01-09 Hamilton O. Hazel Method and apparatus for admixing gas with solid particles
US3425600A (en) * 1966-08-11 1969-02-04 Abplanalp Robert H Pressurized powder dispensing device
US4069819A (en) * 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
GB1479283A (en) * 1973-07-23 1977-07-13 Bespak Industries Ltd Inhaler for powdered medicament
FR2257351A1 (en) * 1974-01-11 1975-08-08 Obert Jean Claude Aerosol device for solid vaccines - feed and breaker screws deliver material sideways into blower chamber
IT1016489B (it) * 1974-03-18 1977-05-30 Isf Spa Inalatore
SU628930A1 (ru) * 1974-11-26 1978-10-25 Московский научно-исследовательский институт туберкулеза Устройство дл введени порошкообразного лекарственного вещества
US3964483A (en) * 1975-01-13 1976-06-22 Syntex Puerto Rico, Inc. Inhalation device
US4005711A (en) * 1975-01-13 1977-02-01 Syntex Puerto Rico, Inc. Inhalation device
FR2299011A1 (fr) * 1975-01-29 1976-08-27 Obert Jean Claude Generateur d'aerosols de part
US3991304A (en) * 1975-05-19 1976-11-09 Hillsman Dean Respiratory biofeedback and performance evaluation system
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
GB1527605A (en) * 1975-08-20 1978-10-04 Takeda Chemical Industries Ltd Insulin preparation for intranasal administration
US3994421A (en) * 1975-09-29 1976-11-30 American Cyanamid Company Unitary therapeutic aerosol dispenser
NL7712041A (en) * 1977-11-01 1979-05-03 Handelmaatschappij Voorheen Be Suction equipment for powdery material - incorporates ejector type suction pump and cyclone type separator
EP0005585B1 (de) * 1978-05-03 1981-08-12 FISONS plc Inhalationsvorrichtung
US4253468A (en) * 1978-08-14 1981-03-03 Steven Lehmbeck Nebulizer attachment
US4503035B1 (en) * 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
SU1003926A1 (ru) * 1979-01-24 1983-03-15 Всесоюзный Научно-Исследовательский И Конструкторский Институт Автогенного Машиностроения Порошковый питатель
IT1116047B (it) * 1979-04-27 1986-02-10 Sigma Tau Ind Farmaceuti Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma
JPS6034925B2 (ja) * 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
US4446862A (en) * 1979-10-30 1984-05-08 Baum Eric A Breath actuated devices for administering powdered medicaments
ZA811942B (en) * 1980-03-25 1983-02-23 H Malem Nebulising apparatus
US4484577A (en) * 1981-07-23 1984-11-27 Key Pharmaceuticals, Inc. Drug delivery method and inhalation device therefor
US5260306A (en) * 1981-07-24 1993-11-09 Fisons Plc Inhalation pharmaceuticals
US4823784A (en) * 1982-04-30 1989-04-25 Cadema Medical Products, Inc. Aerosol inhalation apparatus
US4599311A (en) * 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
GR79615B (de) * 1982-10-08 1984-10-31 Glaxo Group Ltd
US4649911A (en) * 1983-09-08 1987-03-17 Baylor College Of Medicine Small particle aerosol generator for treatment of respiratory disease including the lungs
DE3345722A1 (de) * 1983-12-17 1985-06-27 Boehringer Ingelheim KG, 6507 Ingelheim Inhalator
US4534343A (en) * 1984-01-27 1985-08-13 Trutek Research, Inc. Metered dose inhaler
US4624251A (en) * 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
NZ209900A (en) * 1984-10-16 1989-08-29 Univ Auckland Automatic inhaler
FR2575678B1 (fr) * 1985-01-04 1988-06-03 Saint Gobain Vitrage Ejecteur pneumatique de poudre
US4942544A (en) * 1985-02-19 1990-07-17 Kenneth B. McIntosh Medication clock
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
CH672600A5 (de) * 1985-07-30 1989-12-15 Glaxo Group Ltd
SE453566B (sv) * 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
US4739754A (en) * 1986-05-06 1988-04-26 Shaner William T Suction resistant inhalator
US4790305A (en) * 1986-06-23 1988-12-13 The Johns Hopkins University Medication delivery system
US4926852B1 (en) * 1986-06-23 1995-05-23 Univ Johns Hopkins Medication delivery system phase one
DE3636669C2 (de) * 1986-10-28 2001-08-16 Siemens Ag Anordnung zur Zufuhr von Aerosol zu den Luftwegen und/oder Lungen eines Patienten
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5114917A (en) * 1986-12-24 1992-05-19 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
JP2656944B2 (ja) * 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
IT1222509B (it) * 1987-08-17 1990-09-05 Miat Spa Insufflatore per la somministrazione di farmaci sotto forma di polvere predosata in opercoli
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
US4968607A (en) * 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
WO1989004838A1 (en) * 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5081228A (en) * 1988-02-25 1992-01-14 Immunex Corporation Interleukin-1 receptors
IT1217890B (it) * 1988-06-22 1990-03-30 Chiesi Farma Spa Dispositivo per l'inalazione di aerosol dosati
ATE104867T1 (de) * 1988-10-04 1994-05-15 Univ Johns Hopkins Inhalationsgeraet fuer aerosolen.
US4984158A (en) * 1988-10-14 1991-01-08 Hillsman Dean Metered dose inhaler biofeedback training and evaluation system
DK479189D0 (da) * 1989-01-06 1989-09-28 Hans Gernot Schenk Inhalator
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
IT1228459B (it) * 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
GB8904370D0 (en) * 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
SE466684B (sv) * 1989-03-07 1992-03-23 Draco Ab Anordning vid en inhalator samt foerfarande foer att med anordningen registrera medicinering med inhalator
FI84698C (fi) * 1989-06-16 1992-01-10 Huhtamaeki Oy Anordning foer finfoerdelning av agglomerat av en enkeldos av ett laekemedelpreparat i pulverform.
IT1230313B (it) * 1989-07-07 1991-10-18 Somova Spa Inalatore per medicamenti in capsule.
DE3927170A1 (de) * 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
GB8918879D0 (en) * 1989-08-18 1989-09-27 Danbiosyst Uk Pharmaceutical compositions
US5238920A (en) * 1989-08-22 1993-08-24 Abbott Laboratories Pulmonary surfactant protein fragments
IT1237118B (it) * 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
US5113855A (en) * 1990-02-14 1992-05-19 Newhouse Michael T Powder inhaler
DE4004904A1 (de) * 1990-02-16 1990-09-13 Gerhard Brendel Trommel-applikator
IT1243344B (it) * 1990-07-16 1994-06-10 Promo Pack Sa Inalatore plurimonodose per medicamenti in polvere
US5037912A (en) * 1990-07-26 1991-08-06 The Goodyear Tire & Rubber Company Polymerization of 1,3-butadiene to trans-1,4-polybutadiene with organolithium and alkali metal alkoxide
US5230884A (en) * 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5217004A (en) * 1990-12-13 1993-06-08 Tenax Corporation Inhalation actuated dispensing apparatus
US5099833A (en) * 1991-02-19 1992-03-31 Baxter International Inc. High efficiency nebulizer having a flexible reservoir
US5186164A (en) * 1991-03-15 1993-02-16 Puthalath Raghuprasad Mist inhaler
DE59107894D1 (de) * 1991-03-21 1996-07-11 Ritzau Pari Werk Gmbh Paul Vernebler insbesondere zur Anwendung in Geräten für die Inhalationstherapie
GB9106648D0 (en) * 1991-03-28 1991-05-15 Rhone Poulenc Rorer Ltd New inhaler
US5295479A (en) * 1991-04-15 1994-03-22 Leiras Oy Device intended for measuring a dose of powdered medicament for inhalation
GB9116610D0 (en) * 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
US5161524A (en) * 1991-08-02 1992-11-10 Glaxo Inc. Dosage inhalator with air flow velocity regulating means
GB9123953D0 (en) * 1991-11-12 1992-01-02 Minnesota Mining & Mfg Inhalation device
US5378720A (en) * 1991-12-19 1995-01-03 Sterling Winthrop Inc. Saccharin derivative proteolytic enzyme inhibitors
AU653279B2 (en) * 1991-12-30 1994-09-22 Sanofi Novel 2-saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5320094A (en) * 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
EP0621774B1 (de) * 1992-01-21 1996-12-18 Sri International Verbessertes verfahren zur herstellung von mikronisierter polypeptidarzneimitteln
US5376359A (en) * 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
CZ282964B6 (cs) * 1992-10-19 1997-11-12 Dura Pharmaceuticals, Inc. Inhalátor pro inhalování suchého prášku
US5364838A (en) * 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
US5641510A (en) * 1994-07-01 1997-06-24 Genentech, Inc. Method for treating capsules used for drug storage
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin

Also Published As

Publication number Publication date
US5780014A (en) 1998-07-14
ES2217309T5 (es) 2008-06-01
US5993783A (en) 1999-11-30
EP0866726A4 (de) 1998-09-30
BR9609497A (pt) 1999-03-02
ATE260688T1 (de) 2004-03-15
KR19980703879A (ko) 1998-12-05
WO1996032152A1 (en) 1996-10-17
KR100430125B1 (ko) 2004-08-18
DE69631786T3 (de) 2008-07-24
AU703491B2 (en) 1999-03-25
ES2217309T3 (es) 2004-11-01
MX9707854A (es) 1998-02-28
CA2218208A1 (en) 1996-10-17
JPH10509738A (ja) 1998-09-22
EP0866726A1 (de) 1998-09-30
AU5482596A (en) 1996-10-30
EP0866726B2 (de) 2008-01-09
EP0866726B1 (de) 2004-03-03
DE69631786T2 (de) 2005-03-10

Similar Documents

Publication Publication Date Title
DE69631786D1 (de) Über die lungen verabreichbares trockenpulver alpha 1-antitrypsin
DK0663815T3 (da) Inhalationspulvere og fremgangsmåde til fremstilling heraf
AP1712A (en) Novel tiotropium-containing inhalation powder
HUP0300499A2 (en) Pharmaceutical formulations for dry powder inhalers
SE9701956D0 (sv) New composition of matter
MX9404762A (es) Composiciones para inhalacion y proceso para su preparacion.
KR0179378B1 (en) Powder inhaler
MY115688A (en) Pharmaceutical composition for administration by inhalation
MX9709448A (es) Metodos y sistemas para procesar polvos finos dispersables.
AP1861A (en) Dry powder inhalation system for transpulmonary administration
EE03203B1 (et) Protsess ainete konditsioneerimiseks
DK1019021T3 (da) Stabiliserede præparater til anvendelse i inhalatorer med afmålt dosis
MX9605650A (es) Formulaciones de propionato de fluticasona.
HUP0004053A2 (hu) Eljárás haloterápia kivitelezésére
MXPA04012728A (es) Deshidroepiandrosterona dihidratada y metodos para el tratamiento de asma o una enfermedad pulmonar obstructiva cronica utilizando composiciones de la misma.
JPS6143389B2 (de)
CY1113221T1 (el) Διεργασια για την παρασκευη ενος φαρμακου

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings